This two-piece premium beauty bundle worth £97 is just £55 with our EXCLUSIVE discount code (hurry, offer ends soon!)
Beauty buffs on the hunt for a premium skincare bargain are flocking to Perricone MD to shop their two-piece glow-boosting beauty bundle with money off – and we have an exclusive discount code.
The No Makeup Get The Glow Bundle from Perricone MD features two best-selling products worth £94, designed to leave you looking flawless and radiant - and you can snap it up for just £55 with the code GLOWKIT.
Perricone MD No Makeup Get The Glow Bundle (worth £94)
The perfect way to try two of Perricone MD's unrivalled formulas for less, the No Makeup Get The Glow Bundle features the High Potency Face Finishing & Firming Tinted Moisturiser 59ml and No Makeup Lip Oil in Shade Lychee, an ideal pairing for those no-makeup day looks.
This two-piece set, worth £94, will usually set you back £69 – but you can grab it with an extra £14 off with the code GLOWKIT for a limited time (valid until July 11).
£55 (save £14) Shop
Perfect for the beauty lover looking for an unmissable deal, this two-piece set, which is worth £94, will usually set you back £69 – but you can grab it with an extra £14 off using the code GLOWKIT for a limited time (valid until July 11).
The perfect way to try two of Perricone MD's unrivalled formulas for less, the No Makeup Get The Glow Bundle features the High Potency Face Finishing & Firming Tinted Moisturiser 59m l and No Makeup Lip Oil in Shade Lychee, an ideal pairing for those no-makeup day looks.
Creating luxury skincare products backed by powerful ingredients, cutting-edge research and extensive clinical and consumer studies, Perricone MD is the place to shop if you're looking for real results - and this bundle is no exception.
More than making up for the price of the bundle, the High Potency Face Finishing & Firming Tinted Moisturiser 59ml (£64) is a lightweight, fast-absorbing, tinted moisturiser with SPF30, designed to give you smooth, supple skin in a swipe.
Fast-absorbing and oil-free, this tinted moisturiser delivers powerful antioxidant benefits that help minimise the appearance of wrinkles and imperfections, infusing the skin with essential hydration to keep it looking youthful and radiant.
Plus, thanks to the tinted formula's unique pigment-filled capsules that slowly release upon application, this lightweight moisturiser works well for all skin types, ideal alone or under any foundation for a luminous finish.
The bundle also contains the No Makeup Lip Oil in Shade Lychee, a gorgeously lightweight lip oil that's set to become an essential in your collection.
The non-sticky, skincare-infused lip oil (worth £30) provides just a hint of colour and luminous shine as it instantly replenishes and conditions the lips with essential moisture, working instantly and over time to reduce the look of lip lines for visibly smoother, plumper and more supple lips.
The non-sticky, skincare-infused lip oil (worth £30) provides just a hint of colour and luminous shine as it instantly replenishes and conditions the lips
Users are loving the Perricone MD duo, too, stating how it features 'two of my hero products'.
'The tinted moisturiser will forever be my favourite product from Perricone. Makes life a lot easier as it's a tinted moisturiser and SPF in one. The lip oil feels nourishing too, liking it so far.' One reviewer wrote.
Another added: 'These two are an essential part of my morning routine, the tinted moisturiser is an easy way to smooth skin & the lip oil gives my lips a subtle shine, amazing to get the two with a saving too!'
Yours for just £55 with code GLOWKIT, this stunning duo is a premium beauty bargain you'll want to snap up while you can.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
20 minutes ago
- The Independent
Government urged to enforce a total ban on smacking of children
Campaigners have made a fresh call for laws to ban the smacking of children in England. It comes as belief among young adults that forceful actions against children has grown stronger in recent years, according to a new poll. Wales made any type of corporal punishment, including smacking, hitting, slapping and shaking, illegal in March 2022, while Scotland introduced a similar ban in November 2020. But it is not completely outlawed in England and Northern Ireland. According to the Children Act 2004, it is unlawful to hit your child, except where it is 'reasonable punishment', and this is judged on a case-by-case basis. New polling for the NSPCC, carried out by YouGov, suggests around eight in 10 people (82 per cent) aged between 18 and 24 believe it is unacceptable for a parent to use force, however slight, against a child. This is an increase from 64 per cent of young adults who thought it was unacceptable when polled in 2023. Among parents specifically, the figures have remained high in recent years, with the latest polling showing 81 per cent felt this way, up slightly from 80 per cent last year and from 76 per cent in 2022. YouGov surveyed 3,800 adults across England in July, of which 749 were parents with a child under 18 and 198 were aged 18 to 24 years old. Of all adults surveyed, 71 per cent said they believe physical punishment against a child is unacceptable, up from 67 per cent in 2023. Earlier this year leading health experts came together to urge parliamentarians to give children the 'fundamental right to safety and protection' by backing a smacking ban. The children's doctors and psychiatrists said decades of research showed the 'detrimental effects of physical punishment'. On the latest figures, NSPCC chief executive Chris Sherwood said: 'Parents and young people are telling us loud and clear that they don't want physical punishment to be a part of anyone's childhood. 'Parents know their children and what works best for them. It is therefore crucial their experiences and opinions are not ignored or undermined, but act as a wake-up call. 'As parliamentarians continue to debate the Children's Wellbeing and Schools Bill, we urge them to change the law to better reflect public attitudes to violence against children and ensure no childhood has to be tainted by physical punishment again.' In June, as part of debate on the Bill, Conservative peer Lord Jackson of Peterborough warned that introducing a smacking ban in England would be 'disproportionate and heavy-handed'. He argued 'reasonable chastisement' was harmless and calls to abolish it as a defence for punishing a child risked 'criminalising good and caring parents, as well as overloading children's services departments'. But, in the wake of the murder of 10-year-old Sara Sharif in Woking in 2023, the UK's four children's commissioners jointly called for a wholesale smacking ban, describing the current situation where there is a legal defence in some nations as 'outdated and morally repugnant'. Sara's father – jailed for life in December 2024 alongside her stepmother for the little girl's murder – had claimed in a call to police after fleeing England that he 'did legally punish' his daughter and that he 'beat her up too much'. The children's commissioners insisted 'loving, well-meaning' parents have no need to be concerned about a change in the law. Lynn Perry, chief executive of Barnardo's, said: 'Violence against children is unacceptable – and yet children continue to have less legal protection against physical assault than adults. That cannot be right. This new data shows that most parents agree. 'Physical punishment like smacking is harmful to a child's health and development, and there's strong evidence that it influences their attitudes toward violence. At Barnardo's, we see first-hand how vital it is for children to feel safe and nurtured by those around them and to develop positive, healthy relationships. 'We have long campaigned for a change in the law to give children equal protection from assault and continue to call for action. It's time for all children to be legally protected from all physical punishment everywhere in the UK.' Commenting on the poll, Professor Andrew Rowland, officer for child protection at the Royal College of Paediatrics and Child Health, said: 'This latest research makes it clear that physical punishment has no place in modern parenting. 'Health professionals stand firmly with parents and young people in recognising that physical punishment is not only outdated and unjust, but also harmful to children's health and wellbeing. 'We urge the government to listen to parents, young people, health professionals and the wider public and to finally remove the outdated and unfair 'reasonable punishment' defence.' A Department for Education spokesperson said: 'The landmark Children's Wellbeing and Schools Bill, a key part of our plan for change, represents the most transformative piece of child protection legislation in a generation, including wholesale reform of the children's social care system and better information sharing between education, health, and social workers to stop vulnerable children falling through the cracks. 'While we are looking closely at the legal changes made in Wales and Scotland in relation to smacking, we have no plans to legislate at this stage.'
The Independent
20 minutes ago
- The Independent
New advanced bladder cancer treatment can ‘double chances of survival'
A new treatment for advanced bladder cancer which doubles survival time has been approved for NHS use. The treatment for advanced bladder cancer had not significantly changed since the 1980s. Now, experts say the approval of the new treatment combination would bring a 'fundamental shift' in care for patients with late-stage disease. They said there had been real 'unmet need' for patients with advanced disease, with some 29 per cent of people diagnosed with stage 4 cancer – when the cancer has spread to other parts of the body – surviving for a year after diagnosis. It is estimated that 1,250 people a year could benefit from the treatment. The new treatment combination includes enfortumab vedotin, an antibody-drug which is also known as Padcev, made by Astellas and Pfizer – with pembrolizumab, a drug known as a PD-L1 inhibitor, also known as Keytruda, which is made by Merck. Clinical trials suggest that the treatment combination, when tested against platinum-based chemotherapy, led to improved survival for patients. 'Prior to the EV-302 clinical trial, the treatment of advanced bladder cancer treatment hadn't significantly changed since the 1980s,' Professor Thomas Powles, director of Barts Cancer Institute Biomedical Research Centre (QMUL), UK and primary investigator on the trial, said. 'This guidance will fundamentally reshape first-line treatment for eligible patients.' Trial data indicated that patients who took the treatment combination survived for an average of 33.8 months compared to 15.9 months with chemotherapy. Researchers also measured the amount of time people survived without their disease worsening – also known as progression-free survival – and found that people on the combination treatment had just more than a year of progression-free survival compared to half-a-year for those on standard treatment. Three in 10 (30 per cent) patients had a so-called 'complete response' when getting the combination treatment – meaning there was no evidence of cancer remaining. This was compared to 14.5 per cent of those who received chemotherapy. One patient said that taking part in the trial had given him more time with his grandson. Martyn Hewett, 75, from Stratford, east London, received the combination treatment on a trial at Barts Health NHS Trust after surgery to remove his tumours failed. He said: 'I feel very, very lucky, because if I hadn't been on this trial, I imagine I would be dead by now. 'Immediately after the operation that failed, I asked the doctor what the prognosis was, and he said, most people in your position live for a year, and now, three-and-a-half years later here I am. 'I am going to have an extra few years to see my grandson grow up – and maybe even be around to see him get married.' The treatment combination will now be available for NHS patients in England following the approval from the National Institute for Health and Care Excellence (Nice) for patients with 'unresectable or metastatic urothelial cancer for people who are eligible for platinum-containing chemotherapy' and is given as an IV infusion in hospitals or clinics. Dr Timir Patel, medical director of Astellas UK, said: 'The guidance from Nice is excellent news for patients. 'Advanced bladder cancer is in an area where there is a real unmet need. 'This combination therapy changes the standard of care for doctors and their patients.' Helen Knight, director of medicines evaluation at Nice, said: 'This is a highly promising and effective new drug, with clinical trial results highlighting the tremendous difference it could make to the length and quality of people's lives. 'Advanced bladder cancer is a devastating condition which can have a substantial impact on people's daily lives, often leading to them struggling to work, travel or maintain physical activity.' Professor Peter Johnson, NHS England's national clinical director for cancer, said: 'This is one of the most hopeful advances in decades for people with bladder cancer who will now be offered a treatment that can almost double their chances of survival, helping thousands to live longer and giving them more precious moments with their loved ones. 'Bladder cancer is often difficult to treat once it has spread, but this new therapy is the first one in years to really help stop the disease in its tracks, and our rollout to NHS patients will make a huge difference to the lives of those affected and their families.' Jeannie Rigby, chief executive of charity Action Bladder Cancer UK, said: 'This new drug has the potential to increase how long people have before their cancer gets worse and how long they live compared with the current, limited, treatment choices available.' Around 18,000 people in England are diagnosed with bladder cancer each year.
The Independent
20 minutes ago
- The Independent
Hundreds with rare conditions to benefit from new blood matching test
A new personalised ' blood matching' test has been launched for people with rare conditions who require regular blood transfusions. The move will allow donor blood to be matched to these patients more closely, to reduce the risk of severe reactions. It is the first time it has been used for patients with rare inherited anaemias – with around 300 people eligible for testing, according to NHS Blood and Transplant (NHSBT). The new test uses genetics to generate detailed blood group information. The programme has been backed by the family of toddler Woody Mayers, aged 22 months, who has a rare inherited anaemia called congenital dyserythropoietic anaemia (CDA) type 1. The condition causes the bone marrow to struggle to produce healthy red blood cells, which carry oxygen around the body. It is estimated to affect between one to five out of every million babies. Patients have low haemoglobin levels, meaning Woody relies on blood transfusions every four weeks to stay alive. However, the donor blood must be carefully matched to reduce the risk of patient's developing antibodies against certain blood types, which can cause severe reactions and make transfusions more difficult in the future. The new genotyping testing programme, a partnership between NHSBT and NHS England, uses genetics to identify more of the rarer blood groups. Samples are collected at routine hospital appointments, with patients' DNA tested to find out their blood types. About 300 people with transfusion dependent, rare inherited anaemias, are eligible for the test. All patients with sickle cell disorder and thalassaemia are also eligible, even if they do not rely on blood transfusions. Kate Downes, head of genomics at NHSBT, said: 'The new genotyping test can test blood groups faster and more extensively than standard testing methods.' Professor Dame Sue Hill, chief scientific officer at NHS England, said: 'The power of genomics is transforming medicine, with extended blood group genotyping now being utilised to help patients, especially those requiring regular transfusions. 'This is an exceptional example of an evidence-based innovation, developed from genetic data, being used to drive forward improvements that will make a huge difference across the NHS. 'Blood donations can be lifesaving for patients, and the NHS needs a constant flow of donations to provide people with the best possible care, so I'd encourage anyone who can donate to do so.' Woody's family were alerted to potential health conditions at a 20-week pregnancy scan. He was born prematurely at 34 weeks with haemoglobin levels around a quarter of what they should have been. Woody's mother Polly Mayers, 35, from Robertsbridge in East Sussex, said: 'When he was born, he was very poorly and pale. He didn't cry for a few minutes. He needed ventilation breaths. It was really frightening. 'The first few days were very critical for Woody. He was extremely unwell. Nobody knew the cause for his haemolytic anaemia.' The toddler has now being having regular transfusions fore more than a year, receiving 140mls of red blood cells every four weeks to boost his haemoglobin. Despite this, his family describes him as an energetic little boys who likes trips to the park and riding his bike. His mother added: 'Woody will need the blood to be well-matched so that his transfusions don't become too difficult or risky. 'The test will help him and anyone else with a similar condition. I hope everyone eligible gets it.' Ms Downes said: 'Woody has very rare disorder and he relies on blood transfusions to stay alive but these need to be well matched. 'We want everyone eligible, like Woody, to be tested so they can get better matched blood. We also need more people to donate, so we can supply the matched lifesaving blood to Woody and people like him.' Woody's family are also urging people to donate blood. Mrs Mayers, a community matron, said: 'There's no way to sugar-coat it – if it wasn't for blood donors, Woody would not be alive. 'I'm incredibly grateful to blood donors for ensuring blood is available when he needs it.'
